Meiji Yasuda Asset Management Co Ltd. Purchases New Shares in Edwards Lifesciences Corporation $EW

Meiji Yasuda Asset Management Co Ltd. purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 53,418 shares of the medical research company’s stock, valued at approximately $4,832,000.

A number of other large investors also recently added to or reduced their stakes in EW. Brighton Jones LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at $266,000. NewEdge Advisors LLC grew its holdings in shares of Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after buying an additional 2,665 shares in the last quarter. Sei Investments Co. raised its position in shares of Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares during the last quarter. Squarepoint Ops LLC raised its position in shares of Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after buying an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its stake in shares of Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after buying an additional 1,065 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 0.1%

Shares of NYSE EW opened at $89.89 on Monday. The firm has a market cap of $51.76 billion, a price-to-earnings ratio of 51.66, a PEG ratio of 2.25 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The business’s 50 day moving average is $89.21 and its two-hundred day moving average is $84.68.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period last year, the business posted $0.67 earnings per share. The company’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 25,570 shares of company stock valued at $2,219,390. Corporate insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Mizuho lifted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. UBS Group initiated coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 price objective on the stock. Finally, Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $87.00 to $101.00 in a report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.